MENU

Renal Mass Biopsies May Improve Kidney Cancer Outcomes

November 28, 2016

Rosaleen Parsons, MD, FACRRosaleen Parsons, MD, FACRPHILADELPHIA (November 28, 2016) – The most common type of kidney cancer in adults is renal cell carcinoma, whose incidence and mortality rate have increased over the past few decades. With recent technological advances, radiologists are increasingly using image-guided biopsy of renal masses to optimize treatment strategies for individual patients.

In a single study based on a review of a database assembled over the last 15 years, Fox Chase Cancer Center researchers recently showed that renal mass biopsy enabled accurate diagnosis of renal cell carcinoma. It can also be used to stratify patients based on disease risk — potentially minimizing the risk of over- or under-treatment groups who could be on surveillance versus those who need surgery because of more aggressive renal tumors. The findings will be presented at the annual meeting of the Radiological Society of North America (RSNA) held in Chicago, IL.  

The research team reviewed clinical outcomes of 374 renal mass biopsies performed from 1999 to 2015. Core-needle biopsy, with or without fine-needle aspiration, was performed in 65 percent of cases, 41 percent of which underwent surgical resection. Core-needle biopsy enabled accurate diagnosis of renal cell carcinoma in 94 percent of cases who underwent surgical resection. Moreover, the biopsies successfully identified benign tumors in 11 percent of cases who could undergo surveillance imaging rather than surgery — reducing the risk of over-treatment.

“These findings showed that renal mass biopsy is effective in evaluating renal masses and should be considered in patients where the results would influence clinical decision-making,” said study author Rosaleen Parsons, MD, FACR, Chair of Diagnostic Imaging at Fox Chase.

However, the research revealed important caveats about the potential clinical effectiveness of renal mass biopsy. For example, the biopsies led to inaccurate classifications of tumor grade in 37 percent of surgical cases, putting patients at risk of under-treatment.

In addition, 30 percent of patients who had biopsies and underwent surgery potentially had low-risk tumors, suggesting that they may have been over-treated and better managed by active surveillance. Despite these clinical uncertainties, the findings collectively suggested that renal mass biopsy could improve diagnostic accuracy to assist in clinical management.

“Combining renal mass biopsy with additional clinical pathways for the management of renal masses may help minimize over- and under-treatment risks,” Parsons said. “Balancing competing risks is important and should ultimately guide individualized patient care.”

 

       

The Hospital of Fox Chase Cancer Center and its affiliates (collectively “Fox Chase Cancer Center”), a member of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence five consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.
For more information, call 1-888-FOX CHASE or (1-888-369-2427).

Connect with Fox Chase